Hyperglycemia and vascular metabolic memory: Truth or fiction?

Current Diabetes Reports

Volumn 13, Issue 3, 2013, Pages 403-410

  Bianchi, Cristina ^a   Miccoli, Roberto ^a   Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ACCORD; ADVANCE; Advanced glycation; Epigenetic mechanisms; Glucose control; Hyperglycemia; Intervention trials; Metabolic legacy; ORIGIN; Oxidative stress; Type 1 diabetes; Type 2 diabetes; UKPDS; VADT; Vascular metabolic memory

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN GLARGINE; METFORMIN; PROTEIN KINASE C; PROTEIN KINASE C BETA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SULFONYLUREA; SYNAPTOTAGMIN I;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BRAIN FUNCTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; EPIGENETICS; EVIDENCE BASED PRACTICE; GENE EXPRESSION; GLYCATION; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIPID ANALYSIS; METABOLIC PARAMETERS; METABOLIC REGULATION; MICROANGIOPATHY; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; RETINOPATHY; RISK REDUCTION; SEMANTICS; VASCULAR METABOLIC MEMORY; ANIMAL; BIOLOGICAL MODEL; BLOOD VESSEL; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD VESSELS; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL;

EID: 84877766193     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0371-2     Document Type: Article

References (51)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: a growing challenge. N Engl J Med. 2007;356:213-5. (Pubitemid 46143224)
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. Global burden of metabolic risk factors of chronic diseases collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31-40.
3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88:1254-64.
4. Raman R, Gupta A, Krishna S, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complicat. 2012;26:123-8.
5. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241:2035-8. (Pubitemid 9228506)
6. Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA, Shekelle RB, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986;123:504-16. (Pubitemid 16101155)
7. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, The Emerging Risk Factors Collaboration, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.
8. Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. (Pubitemid 351831356)
9. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351214289)
10. Duckworth W, Abraira C, Moritz T, et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39.
11. Turnbull F, Zoungas S. Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomized controlled trials? Evid Based Med. 2012;17:98-9.
12. Del Prato S. Mega-trials in type 2 diabetes. From excitement to frustration? Diabetologia. 2009;52:1219-26.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53. (Pubitemid 28416718)
14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
15. DCCT Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86. (Pubitemid 23307905)
16. Diabetes control and complications trial/epidemiology of diabetes interventions and complications research group prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus. Ten years after the diabetes control and complications trial. Arch Ophthalmol. 2008; 126:1707-15.
17. Martin CL, Waberski BH, Pop-Busui R, Cleary PA, Catton S, Albers JW, et al. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care. 2010;33:2635-41.
18. Pop-Busui R, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, et al. Association between cardiovascular autonomic neuropathy and left ventricular dysfunction in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. J Am Coll Cardiol. 2013;61:447-54.
19. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366-76. This is the most recent paper from the DCCT/EDIC investigators confirming persistent beneficial effects in type 1 diabetic patients with initial intensive vs conventional treatment.
20. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53. (Pubitemid 41817713)
21. Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analyzing the DCCT with respect to time-dependent effects. Diabetologia. 2010;53:1093-8.
22. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93. (Pubitemid 36159355)
23. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. (Pubitemid 351214285)
24. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff Jr DC, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-28.
25. Reaven PD, Moritz TE, Schwenke DC, Anderson RJ, Criqui M, Detrano R, et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in Veterans Affairs Diabetes Trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009;58:2642-8.
26. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION Europe): a cluster-randomized trial. Lancet. 2011;378:156-67.
27. Yang Y, Yao JJ, Du JL, Bai R, Sun LP, Sun GH, et al. Primary prevention of macroangiopathy in patients with short-duration type 2 diabetes by intensified multifactorial intervention: seven-year follow-up of diabetes complications in Chinese. Diabetes Care. 2012. doi: 10.2337/dc12-0227
28. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28.
29. The ORIGINALE Study. http://origintrial.org/Assets/PDF/ ORIGINALE%20Protocol.pdf. Accessed on January 3, 2013.
30. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes. 1987;36:808-12. (Pubitemid 17145301)
31. Hammes HP, Klinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Invest Ophthalmol Vis Sci. 1993;34:2092-6. (Pubitemid 23148648)
32. Kowluru RA. Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes. 2003;52:818-23. (Pubitemid 36323591)
33. Kowluru RA, Chakrabarti S, Chen S. Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-kappaB) in the retina. Acta Diabetol. 2004;41:194-9. (Pubitemid 40174996)
34. Kowluru RA, Kanwar M, Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res. 2007;2007:21976.
35. Kowluru RA, Chan PS. Metabolic memory in diabetes - from in vitro oddity to in vivo problem: role of apoptosis. Brain Res Bull. 2010;81:297-302.
36. Kowluru RA, Abbas SN, Odenbach S. Reversal of hyperglycemia and diabetic nephropathy: effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats. J Diabetes Complicat. 2004;18:282-8. (Pubitemid 39165435)
37. Roy S, Sala R, Cagliero E, Lorenzi M. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A. 1990;87:404-8. (Pubitemid 20033079)
38. Brownlee M. The pathobiology of diabetes complications: a unifying mechanism. Diabetes. 2005;54:1615-25. (Pubitemid 40770750)
39. Stitt AW. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol. 2003;1:95-108. (Pubitemid 36798117)
40. Siebel AL, Fernandez AZ, El-Osta A. Glycemic memory associated epigenetic changes. Biochem Pharmacol. 2010;80:1853-9.
41. Cooper ME, El-Osta A. Epigenetics: mechanisms and implications for diabetic complications. Circ Res. 2010;107:1403-13. This study provides a thorough description of the current understanding the molecular changes to chromatin structure and the functional relationship with altered signaling pathways that represents the basis of metabolic memory.
42. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409-17.
43. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20. (Pubitemid 34000785)
44. Ihnat MA, Thorpe JE, Kamat CD, Szabó C, Green DE, Warnke LA, et al. Reactive oxygen species mediate a cellular 'memory' of high glucose stress signaling. Diabetologia. 2007;50:1523-31. (Pubitemid 46879013)
45. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive vs conventional therapy of type 1 diabetes: relevance of glycated collagen products vs HbA1c as markers of diabetic complications. Diabetes. 1999;48:870-80. (Pubitemid 29153089)
46. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes. 2005;54:3103-11. (Pubitemid 43334362)
47. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59:1244-53.
48. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care. 2010;33:1090-6.
49. Polak JF, Backlund JY, Cleary PA, Harrington AP, O'Leary DH, Lachin JM, et al. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes. 2011;60:607-13.
50. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-3. (Pubitemid 46906618)
51. Doria A, Wojcik J, Xu R, Gervino EV, Hauser TH, Johnstone MT, et al. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA. 2008;300:2389-97.